Logo image of ADTX

ADITXT INC (ADTX) Stock Fundamental Analysis

NASDAQ:ADTX - Nasdaq - US0070257037 - Common Stock - Currency: USD

0.0958  -0.01 (-12.91%)

Premarket: 0.0976 +0 (+1.88%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ADTX. ADTX was compared to 572 industry peers in the Biotechnology industry. ADTX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ADTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADTX has reported negative net income.
ADTX had a negative operating cash flow in the past year.
ADTX had negative earnings in each of the past 5 years.
ADTX had a negative operating cash flow in each of the past 5 years.
ADTX Yearly Net Income VS EBIT VS OCF VS FCFADTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of ADTX (-154.99%) is worse than 85.49% of its industry peers.
ADTX's Return On Equity of -981.55% is on the low side compared to the rest of the industry. ADTX is outperformed by 83.72% of its industry peers.
Industry RankSector Rank
ROA -154.99%
ROE -981.55%
ROIC N/A
ROA(3y)-203.04%
ROA(5y)-1107.46%
ROE(3y)-396.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADTX Yearly ROA, ROE, ROICADTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADTX Yearly Profit, Operating, Gross MarginsADTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

0

2. Health

2.1 Basic Checks

ADTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADTX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ADTX has more shares outstanding
Compared to 1 year ago, ADTX has a worse debt to assets ratio.
ADTX Yearly Shares OutstandingADTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20K 40K 60K 80K 100K
ADTX Yearly Total Debt VS Total AssetsADTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -11.83, we must say that ADTX is in the distress zone and has some risk of bankruptcy.
ADTX's Altman-Z score of -11.83 is on the low side compared to the rest of the industry. ADTX is outperformed by 78.58% of its industry peers.
ADTX has a Debt/Equity ratio of 1.88. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.88, ADTX is doing worse than 82.30% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.88
Debt/FCF N/A
Altman-Z -11.83
ROIC/WACCN/A
WACC24.58%
ADTX Yearly LT Debt VS Equity VS FCFADTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 0.09 indicates that ADTX may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.09, ADTX is doing worse than 98.58% of the companies in the same industry.
A Quick Ratio of 0.08 indicates that ADTX may have some problems paying its short term obligations.
ADTX has a Quick ratio of 0.08. This is amonst the worse of the industry: ADTX underperforms 98.76% of its industry peers.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.08
ADTX Yearly Current Assets VS Current LiabilitesADTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

ADTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.22%, which is quite impressive.
Looking at the last year, ADTX shows a very negative growth in Revenue. The Revenue has decreased by -71.89% in the last year.
EPS 1Y (TTM)81.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-127.72%
Revenue 1Y (TTM)-71.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-94.5%

3.2 Future

The Earnings Per Share is expected to grow by 40.13% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 395.36% on average over the next years. This is a very strong growth
EPS Next Y99.83%
EPS Next 2Y40.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year45.65%
Revenue Next 2Y395.36%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

ADTX Yearly Revenue VS EstimatesADTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
ADTX Yearly EPS VS EstimatesADTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20K -40K -60K -80K -100K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ADTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADTX Price Earnings VS Forward Price EarningsADTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADTX Per share dataADTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2K -4K -6K

4.3 Compensation for Growth

ADTX's earnings are expected to grow with 40.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.13%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ADTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADITXT INC

NASDAQ:ADTX (2/4/2025, 8:25:13 PM)

Premarket: 0.0976 +0 (+1.88%)

0.0958

-0.01 (-12.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners0.45%
Inst Owner Change0%
Ins Owners0.09%
Ins Owner Change-0.76%
Market Cap1.36M
Analysts80
Price TargetN/A
Short Float %10.39%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-92.9%
Min Revenue beat(2)-98.21%
Max Revenue beat(2)-87.6%
Revenue beat(4)0
Avg Revenue beat(4)-75.66%
Min Revenue beat(4)-98.21%
Max Revenue beat(4)-40.89%
Revenue beat(8)0
Avg Revenue beat(8)-60.52%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.43
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-6960.8
EYN/A
EPS(NY)-252.96
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0.01
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -154.99%
ROE -981.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.04%
ROA(5y)-1107.46%
ROE(3y)-396.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 1.88
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.08
Altman-Z -11.83
F-Score3
WACC24.58%
ROIC/WACCN/A
Cap/Depr(3y)94.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)323.1%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-127.72%
EPS Next Y99.83%
EPS Next 2Y40.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-71.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-94.5%
Revenue Next Year45.65%
Revenue Next 2Y395.36%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.84%
OCF growth 3YN/A
OCF growth 5YN/A